Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer

Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer Pancreatic cancer is the fourth leading cause of cancer-related death in North America and is associated with an extremely bleak prognosis. Advances in the treatment of this devastating disease will require novel approaches. A key therapeutic strategy is inhibition of the epidermal growth factor receptor (EGFR). The EGFR is overexpressed in pancreatic cancer and is associated with poor prognosis. This article summarizes current knowledge of the role of EGFR antagonists in pancreatic cancer and focuses on the preclinical background and EGFR inhibitors in clinical development including erlotinib, gefitinib, cetuximab, and matuzumab. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer

American Journal of Cancer , Volume 5 (4) – Aug 9, 2012

Loading next page...
 
/lp/springer-journals/epidermal-growth-factor-receptor-antagonists-in-pancreatic-cancer-zOLjQOkcxV
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605040-00002
Publisher site
See Article on Publisher Site

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death in North America and is associated with an extremely bleak prognosis. Advances in the treatment of this devastating disease will require novel approaches. A key therapeutic strategy is inhibition of the epidermal growth factor receptor (EGFR). The EGFR is overexpressed in pancreatic cancer and is associated with poor prognosis. This article summarizes current knowledge of the role of EGFR antagonists in pancreatic cancer and focuses on the preclinical background and EGFR inhibitors in clinical development including erlotinib, gefitinib, cetuximab, and matuzumab.

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

References